Lonza Group (LZAGY) Stock Price, News & Analysis

Company Overview

Lonza Group is a Basel, Switzerland–based multinational life sciences company specializing in the development, manufacturing and support of products for the pharmaceutical, biotechnology and specialty ingredients markets. As a leading contract development and manufacturing organization (CDMO), Lonza offers end-to-end solutions ranging from early-stage process development and clinical supply through commercial manufacturing of small molecules, biologics, cell and gene therapies. In addition, the company produces a range of chemical intermediates and microbial control products for the consumer care, agriculture and industrial sectors.

Founded in 1897 in the Swiss canton of Valais to exploit local hydropower for acetylene production, Lonza has evolved through decades of innovation and strategic acquisitions. The company expanded its footprint into the United States and Asia in the 1970s and 1980s, and more recently strengthened its biologics capabilities with the acquisition of Capsugel from Pfizer in 2017. Over its history, Lonza has consistently reinvested in facility expansions, bioprocess technologies and quality-assurance systems to meet the stringent regulatory requirements of global health authorities.

Lonza’s core offerings include active pharmaceutical ingredient (API) synthesis, formulation development, aseptic filling and packaging services, as well as cell-therapy and viral-vector manufacturing. Its specialty ingredients division delivers antimicrobial preservatives, cosmetic actives and nutritional ingredients that serve customer formulations across personal care, home care and food markets. Complementing these capabilities, Lonza provides technical support, regulatory guidance and supply-chain services designed to accelerate time to market and ensure product consistency at commercial scale.

The company maintains a global network of research, development and manufacturing sites across Europe, North America and the Asia-Pacific region, employing a multidisciplinary workforce of scientists, engineers and regulatory specialists. As of January 2022, Albert Baehny serves as Chief Executive Officer, leading a management team focused on sustainable growth, operational excellence and customer-centric innovation for the life sciences and specialty ingredients industries.

Key Stats

• Today's Range: $72.14 to $72.66
• 50-Day Range: $66.43 to $72.49
• 52-Week Range: $55.57 to $73.29
• Volume: 76,737 shs
• Average Volume: 28,252 shs
• Market Capitalization: $50.82 billion
• P/E Ratio: N/A
• Dividend Yield: 0.14%
• Price Target: N/A
• Consensus Rating: Strong Buy

Lonza Group Stock Analysis - MarketRank™

Lonza Group scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Lonza Group.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 15.43%

Earnings Growth

Earnings for Lonza Group are expected to grow by 15.43% in the coming year, from $1.88 to $2.17 per share.

Price to Earnings Growth Ratio

Lonza Group has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Lonza Group has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of Lonza Group have been sold short.

Short Interest Ratio / Days to Cover

Lonza Group has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lonza Group has recently decreased by 41.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Lonza Group has a dividend yield of 0.15%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Lonza Group does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Lonza Group will have a dividend payout ratio of 4.61% next year. This indicates that Lonza Group will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of Lonza Group have been sold short.

Short Interest Ratio / Days to Cover

Lonza Group has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lonza Group has recently decreased by 41.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.50

News Sentiment

Lonza Group has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Lonza Group this week, compared to 1 article on an average week.

Search Interest

1 people have searched for LZAGY on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lonza Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.07% of the stock of Lonza Group is held by insiders.

Percentage Held by Institutions

Only 0.04% of the stock of Lonza Group is held by institutions.

LZAGY Stock Analysis - Frequently Asked Questions

How have LZAGY shares performed this year?

Lonza Group's stock was trading at $58.78 at the start of the year. Since then, LZAGY shares have increased by 23.1% and is now trading at $72.36.

Does Lonza Group have any subsidiaries?

Lonza Group subsidiaries include Octane Biotech, Micro-Macinazione, Capsugel, PharmaCell, InterHealth Nutraceuticals, Triangle Research Labs, Diacon Technologies, and more.

How do I buy shares of Lonza Group?

Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LZAGY
• CIK: 1446711
• Web: www.lonza.com
• Phone: (161) 316-8111
• Fax: 41-61-316-9111
• Employees: 18,686
• Year Founded: 1897

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 38.49
• P/E Growth: 2.17
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 1.52
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: $7.47 billion
• Price / Sales: 6.80
• Cash Flow: $2.40 per share
• Price / Cash Flow: 30.19
• Book Value: $14.76 per share
• Price / Book: 4.90

Miscellaneous

• Outstanding Shares: 702,290,000
• Free Float: 701,798,000
• Market Cap: $50.82 billion
• Optionable: Not Optionable
• Beta: 1.15